NCT07643428
Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors
Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatmentMedical College of WisconsinInvestigator-initiated
~35 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Mini rTG OMEGA-3 Fish Oil
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Lipid species in primary breast tumors
Measured over Up to 32 weeks
Conditions
Where it's being run
1 sites across 1 statesWisconsin1
Study leadership
- Lubna Chaudhary, MD, MS · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin
Who to contact
Medical College of Wisconsin Cancer Center Clinical Trials Office
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patient must be ≥18 years of age.
Breast tumor ≥1 cm.
Not currently taking dietary supplements containing fish oil or omega-3 PUFAs. A diet containing fish meat is permitted.
Unilateral and/or bilateral diagnostic breast mammogram and/or ultrasound within 60 days of enrollment. If breast MRI is done per treating physician's discretion, at least one breast imaging modality should be within 60 days of enrollment.
Pathologically proven diagnosis of invasive breast cancer, clinical stage I-III (cT1c-T4, N0-N3, M0).
Concurrent (neoadjuvant) systemic anti-cancer therapy is planned, including but not limited to endocrine therapy, chemotherapy, anti-HER2 therapy, and immunotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Bilateral breast cancer and/or multifocal, multicentric disease is allowed.
Appropriate pretreatment evaluations for protocol entry, including no clinical evidence for distant metastases, based upon the following minimum diagnostic workup: history/physical examination, including breast exam (inspection and palpation of the breasts), within 30 days prior to study entry.
Patients with a prior history of breast cancer will be considered eligible.
Surgical candidacy as determined by the treating physician.
Patient must provide study-specific informed consent prior to study entry or have a legally authorized representative provide consent.
Exclusion
American Joint Committee on Cancer (AJCC) clinical M1 breast cancer (i.e., with distant metastasis).
Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ).
Medical, psychiatric, or other condition that would prevent the patient from receiving the protocol treatment or providing informed consent.
What this trial measures
- Lipid species in primary breast tumorsUp to 32 weeks
The number of subjects with increased levels of DHA-containing and EPA-containing lipid species in primary breast tumors.